Abcombi Completes I-Corps at NIH Program for Influenza Indication

On March 28th, Abcombi representatives completed the February-March 2017 I-Corps at NIH program in which we refined the company’s strategy for our influenza therapeutic. The representatives for the program were Andrew Hill (C-level Corporate Officer), Dr. Charles Jones (PI), and Chris Kilgore (Industry Expert).  Over the course of the I-Corps, our team refined the commercialization strategy of our influenza therapeutic and identified key research areas that we will address in future work.